Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $1.9 million.

  • Tarsus Pharmaceuticals' Non Operating Income rose 1159.59% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 126.25%. This contributed to the annual value of $5.0 million for FY2024, which is 3097.04% down from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Non Operating Income stood at $1.9 million for Q3 2025, which was up 1159.59% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Non Operating Income registered a high of $2.5 million during Q4 2023, and its lowest value of -$908000.0 during Q2 2021.
  • In the last 5 years, Tarsus Pharmaceuticals' Non Operating Income had a median value of $1.3 million in 2024 and averaged $849684.2.
  • In the last 5 years, Tarsus Pharmaceuticals' Non Operating Income crashed by 842500.0% in 2021 and then soared by 293692.31% in 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Non Operating Income (Quarter) stood at -$349000.0 in 2021, then soared by 518.91% to $1.5 million in 2022, then soared by 74.28% to $2.5 million in 2023, then crashed by 48.67% to $1.3 million in 2024, then skyrocketed by 48.62% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $1.8 million for Q2 2025, and $1.2 million during Q1 2025.